Physician profile
Aaron M Locklear
NPI 1265852685
$3,053.40
in general payments reported to CMS, 2019-2025
25 companies · $976 in 2025
The $976 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $518 · 2020: $149 · 2021: $14.98 · 2022: $25.79 · 2023: $637 · 2024: $733 · 2025: $976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,346.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $517.29 | 2022-2025 | |
| Novo Nordisk INC | $516.52 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $285.39 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Ardelyx, INC. | $252.94 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $210.53 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Phathom Pharmaceuticals, INC. | $144.10 | 2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $129.66 | 2019-2024 | Trulance, Xifaxan |
| Corcept Therapeutics | $128.50 | 2023-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.66 | 2019-2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $100.29 | 2023-2025 | Caplyta |
| Amgen INC. | $96.14 | 2019-2024 | Repatha, Otezla |
| Pfizer INC. | $88.08 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $77.07 | 2019-2024 | Trintellix |
| Allergan, INC. | $76.35 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $64.03 | 2019-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $43.42 | 2019-2024 | Arexvy, Shingrix |
| Exact Sciences Corporation | $37.50 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $35.80 | 2023-2025 | Rexulti |
| Boston Scientific Corporation | $32.36 | 2025 | Wavewriter Alpha Prime 16 |
| Organogenesis INC. | $31.21 | 2025 | Puraply Wound Matrix |
| Dynavax Technologies Corporation | $29.36 | 2024-2025 | Heplisav-B |
| Dexcom, INC. | $15.55 | 2023 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $14.98 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.63 | 2023 | |
| Merck Sharp & Dohme LLC | $11.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Locklear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.